Assessment of the INVOcell Culture Device When Used for up to Five-Day Incubation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a single center, open label non-comparative prospective trial to evaluate the retention of the INVOcell IVC with the Retention Device over the vaginal incubation period of up to 5 days.
The purpose of this study is to assess the retention of the INVOcell IVC device with the Retention Device over the vaginal incubation period of up to 5 days.
Primary Endpoint
• Retention of the INVOcell IVC device with the Retention Device over the vaginal incubation period of up to 5 days.
Secondary Endpoint
- Comfort of the INVOcell IVC and Retention Device
- Vaginal tissue reactions during the vaginal incubation
- Optical clarity and the ability to visualize the embryos after the incubation
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Homewood, Alabama, United States, 35209
- American Institute of Reproductive Medicine/IVF Alabama (AIRM)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have been informed about the study and have given their written consent.
- Patients 18 years to 42 years
- Women who are scheduled for an oocyte retrieval in anticipation of INVOcell IVF.
Exclusion Criteria:
- Inability to read and speak English fluently
- Identified vaginal infection
- Recent pelvic surgery based on clinical history and physical examination.
- History of toxic shock syndrome
- Inability to tolerate the placement or wearing of the INVOcell IVC or INVOcell Retention Device.
- Inability to tolerate a speculum examination
- Unwilling or unable to wear the INVO Retention (diaphragm) during the incubation.
- Unable or unwilling to sign informed consent or abide by study follow up assessment requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment Group
During an IVF/IVC cycle, participants will retain the INVOcell Culture Device with the Retention Device in the vaginal cavity for 5 days vaginal incubation
|
Female participants undergoing in vitro fertilization (IVF) and or/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproductive will be asked to participate
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Device Retention
Time Frame: 5 days
|
The primary endpoint is INVOcell IVC retention with the Retention Device. The following will be assessed: Whether the INVOcell IVC stays in place (is retained within the vaginal cavity) while being used with the Retention Device during 5 days of continuous vaginal incubation. |
5 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comfort
Time Frame: 5 days
|
Comfort of the INVOcell IVC while worn with the Retention Device evaluated on a 10-oint Likert scale.
|
5 days
|
|
Vaginal tissue reactions
Time Frame: 5 days
|
Vaginal tissue reactions during the vaginal incubation based on post removal and assessed by vaginal speculum examination performed to examine the vaginal walls speculum examination post removal vaginal examination.
|
5 days
|
|
Optical clarity
Time Frame: 5 days
|
Optical clarity and the ability to visualize the embryos after the incubation of the INVOcell device.
|
5 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Karen Hammond, DNP, CRNP, American Institute of Reproductive Medicine/IVD Alabama (AIRM)
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CP-018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.